Organigram GlobalSTU:0OG +7.60%64 Current Ratio is 2.82 as of Mar. 2026, which is 43% below its 10-year median of 4.92. GuruFocus rates STU:0OG with a GF Score™ of 64/100 and a GF Value™ of €1.47 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 995 Drug Manufacturers companies, Organigram Global ranks better than 65.13% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Organigram Global's current ratio for the quarter that ended in Mar. 2026 was 2.82.
Organigram Global has a current ratio of 2.82. It generally indicates good short-term financial strength.
The historical rank and industry rank for Organigram Global's Current Ratio or its related term are showing as below:
STU:0OG'
s Current Ratio Range Over the Past 10 Years
Min: 1.87 Med: 4.92 Max: 20.63
Current: 2.82
During the past 13 years, Organigram Global's highest Current Ratio was 20.63. The lowest was 1.87. And the median was 4.92.
STU:0OG's Current Ratio is ranked better than 65.13% of 995
companies
in the Drug Manufacturers industry
Industry Median: 2
vs STU:0OG: 2.82
Organigram Global (STU:0OG) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Organigram Global Current Ratio Related Terms
Organigram Global Current Ratio Historical Data
* Premium members only.
The historical data trend for Organigram Global's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Organigram Global's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organigram Global Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organigram Global's Current Ratio distribution charts can be found below:
* The bar in red indicates where Organigram Global's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organigram Global (STU:0OG) has a Current Ratio of 2.82 as of Mar. 2026. This is 43% below median its historical median of 4.92. Over the past decade, Organigram Global's Current Ratio has ranged from 1.87 to 20.63. According to the industry distribution chart, Organigram Global ranks #347 out of 995 companies in the Drug Manufacturers industry, placing it in the top 34.9%.
Is Organigram Global's Current Ratio too high?
Organigram Global's current Current Ratio of 2.82 is 43% below median its 10-year median of 4.92. Over the past 10 years, this metric has ranged from a low of 1.87 to a high of 20.63. The Drug Manufacturers industry median Current Ratio is 2.00. Organigram Global's value of 2.82 is 41% above this industry median. Based on the distribution chart, Organigram Global ranks #347 out of 995 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Organigram Global has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Organigram Global's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Organigram Global ranks #347 out of 995 companies for Current Ratio. This puts Organigram Global in the upper half of its industry. The industry median Current Ratio is 2.00. Organigram Global's value of 2.82 is 41% above this benchmark. Historically, Organigram Global's own Current Ratio has ranged from 1.87 to 20.63 over the past decade. While the company's 10-year median is 4.92 vs. the industry median of 2.00, Organigram Global has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organigram Global's current Current Ratio of 2.82 is 41% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organigram Global's current Current Ratio is 2.82, which is 43% below median its own 10-year median of 4.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organigram Global stock overvalued right now?
Based on GuruFocus' analysis, Organigram Global (STU:0OG) is currently considered Possible Value Trap. The stock's GF Value™ is €1.47, compared to a current price of €0.88 — trading 40.3% below its estimated fair value. The current Current Ratio is 2.82, which is 43% below median its 10-year median of 4.92 and 41% above the Drug Manufacturers industry median of 2.00. Organigram Global's overall GF Score™ is 64/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Organigram Global (STU:0OG), the current Current Ratio is 2.82 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organigram Global (STU:0OG) Overvalued in 2026?
Based on GuruFocus' analysis, Organigram Global stock appears to be undervalued.
The current stock price of €0.88 is trading 40.3% below its estimated GF Value™ of €1.47.
GuruFocus considers Organigram Global to be Possible Value Trap.
Key valuation signals for STU:0OG:
Current Ratio: 2.82 (43% below median its 10-year median of 4.92)
GF Value™: €1.47 vs. price of €0.88 (40.3% below fair value)
Industry Position: 41% above the Drug Manufacturers median (#347 of 995)
No single metric tells the full story. See the STU:0OG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
64GF Score
Get the complete analysis for STU:0OG
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0OG has been successfully added to your 
